The ProHeart 12 formulation is the same as the previously approved product but contains three times the concentration of moxidectin, resulting in a 12-month duration of action. Moxidectin is a macrocyclic lactone antiparasitic compound already approved in an extended release formulation as ProHeart 6, with a six-month duration of action for heartworm disease prevention. In the United States, heartworm disease has historically been most common along the Atlantic and Gulf coasts from the Gulf of Mexico to New Jersey and along the Mississippi River and its major tributaries, but it has been reported in dogs in all 50 states. The worms are called "heartworms” because the adults live in the heart, lungs, and associated blood vessels of an infected animal. While living inside a dog, the worms mature into adults, mate, and produce offspring.
The worms are spread through the bite of a mosquito. It is caused by a parasitic roundworm called Dirofilaria immitis. Heartworm disease is a serious disease that results in severe lung disease, heart failure, other organ damage, and death in pets, mainly dogs, cats, and ferrets. ProHeart 12 is also approved for the treatment of existing larval and adult hookworm infections. Food and Drug Administration’s Center for Veterinary Medicine announced today the approval of ProHeart 12 (moxidectin) extended-release injectable suspension for dogs 12 months of age and older for the prevention of heartworm disease caused by Dirofilaria immitis for 12 months.
0 kommentar(er)
